THE NITROIMIDAZOLE DRUG misonidazole (MISO) is an effective radiosensitizer of hypoxic mammalian cells. It is hoped that MISO, or a similar compound, will overcome the radioresistance of tumours that contain hypoxic cells. Clinical trials are under way. It appears, however, that the usefulness of MISO may be limited by its production of dose-limiting side effects, such as peripheral neuropathy (Urtasun et al., 1977; Dische et al., 1978; Wasserman et al., 1980) . MISO is selectively toxic to hypoxic cells in vitro, even in the absence of radiation (Moore et al., 1976; Hall & Roizin-Towle, 1975 (Taylor & Rauth, 1978; Wong et al., 1978) . This supports the idea that hypoxic toxicity may result from the formation of reactive nitroreduction products (Varghese et al., 1976; Josephy et al., 1978; Taylor & Rauth, 1978) . Furthermore ascorbic acid, a reducing agent which enhances the production of such metabolites (Taylor & Rauth, 1 980a, b) , greatly increases the hypoxic toxicity of MISO (Josephy et al., 1978) .
Separation of MISO metabolites has been achieved by paper chromatography (Varghese et al., 1976) . However, the efficiency of this technique is inferior to that of thin-layer chromatography (TLC) and high-pressure liquid chromatography (HPLC); the procedure is also much slower. Paper chromatography provided some evidence for co-chromatography of certain metabolites with the products of zinc reduction of MISO (Varghese et al., 1976) but conclusive identification of the cellular products has not yet been presented.
Recently we have studied the reduction of MISO by the hypoxanthine/xanthine oxidase system under hypoxia (Josephy et al., 1981) . A single major product is formed, which stoichiometry and mass spectroscopy suggest is the hydroxylamine derivative of MISO. Analogous results have been obtained by radiationchemical reduction of the drug (Whillans & Whitmore, 1980 (Josephy et al., 1978) .
Cells were diluted daily to about 7 x 104 cells/ ml, except for the final 24 h before an experiment, when they were allowed to reach 5 x 105 cells/ml. Cells (3 x 108) A-ere harvested by centrifugation and spun to form a pellet of about 1 ml. The pellet was then resuspended in of medium containing 14C-MISO to give a total volume of 2 ml and a drug concentration of 0-38 mm. This concentration corresponds to the plasma concentration achieved in clinical trials, following oral administration of a dose of about 0-2 mmol/kg (Workman. 1980) . At zero time the tube was transferred to a 37°C water bath. Water-saturated 02-free N2 was flowed over the suspension throughout the experiment. The suspension wvas vortexed occasionally to prevent sedimentation and adherence of the cells. Samples, each 0 3 ml, were removed shortly after zero time (within 2 min) and at each hour up to 3 h. The samples were then processed according to the scheme shown in Table I . Each sample was added to 1-7 ml distilled H20 and sonicated for 10 sec using a Branson cell disruptor with microtip. An aliquot of the sonicate was dissolved in 05 ml of 2M NaOH, neutralized with acetic acid and counted to determine total activitv. The remainder of the sonicate wras frozen and lyophilized to dryness. The dry residue was resuspended with ethyl acetate/methanol (63%/37%), spun (5 min at 800 rev/min), and the supernatant decanted. This procedure wNas repeated x 3; the supernatants were combined and evaporated in a Buchler vortex evaporator at 30°C. The dry samples wNere stored at -15°C until chromatographed. The samples were not stored more than one week before chromatography. No change in chromatographic profiles wvas observed during storage.
Pellets.-In preliminary experiments, we studied the pellets remaining after the above extraction. The pellets contained acidsoluble activity which rose wvith time of incubation to -5000 of total activity, and acid-insoluble activity rising from 0 to -10% of total activity. Presumably, these represent MISO metabolites that are bound to small molecules and macromolecules respectively (Varghese & Whitmore, 1980b) . To quanti- The nature of the acid-soluble material has not been studied in detail. These metabolites are highly polar (Rf almost zero on TLC) and may include ionic conjugates such as glucuronides or sulphates. The pellet contains activity bound (probably covalently) to nucleic acid and protein. Similar results have been obtained both in vitro and in vivo (Varghese & Whitmore, 1980a (Josephy et al., 1980) . Recently, Varghese & Whitmore (1 980a, b) described another procedure, reduction with zinc at 37'C in the presence of NH4Cl. Again, several products resulted, apparently including the azo, azoxy, and possibly, hydroxylamine derivatives.
The enzymatic (Josephy et al., 1981) and radiation-chemical (Whillans & Whitmore, 1980) (Wardman, 1977) .
In this paper, we have shown that a metabolite of MISO, produced in hypoxic cells, is identical to the enzymic product. This metabolite can be detected after a very brief exposure to MISO (Fig. 3a) and, after the disappearance of the parent drug, it remains the major organicsoluble metabolite.
The in vitro metabolism of 14C-MISO has been studied previously (e.g. Taylor & Rauth, 1978 Varghese et al., 1976; Whitmore et al., 1978) . In the present paper, however, we have used labelled drug with more than 1-00-fold specific activity. Also, we have separated organicsoluble material from the cell extracts before chromatography. The organicinsoluble, acid-soluble material represents at least half the metabolite activity; since this material is very polar, it would elute early on a reversed-phase column, and might obscure the metabolites seen in Figs 3 and 4. We consider it unlikely that the reduced product identified in this paper corresponds to one of the peaks (e.g. P1, P2) seen in paper chromatography of crude extracts of CHO cells (Taylor & Rauth, 1978) .
WVe believe that our results are consistent with the scheme shown in Table II . Reductive activation proceeds in hypoxia, and 02 inhibits this pathway, probably by reoxidation of the initial one-electron reduction product of MISO, the nitroanion free radical (Mason & Holtzman, 1975; Sealy et al., 1978) . The first relatively stable nitroreduction product to be formed is probably the hydroxylamine, the nitroso compound being reduced too rapidly to be detected. An analogous mechanism has been demonstrated for nitrobenzene reduction (Wardman 1977, p. 371). The hydroxylamine may be further reduced to the amine, which is probably a urinary excretion product in man deed, the formation of azo and azoxy dimers during chemical reduction (Josephy et al., 1980) is probably a consequence of the reactivity of intermediates such as the nitroso compound. Finally, it should be noted that the processes shown in Table II are not mutually exclusive; for example, demethylation could be followed by reduction, or reduction by conjugation. Indeed such "twicemetabolized" products may be quantitatively predominant, particularly in the organic-insoluble, acid-soluble fraction.
